Alkimia Pharma-Chem Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 27.61%
(FY 2023)
- Profit -199.63%
(FY 2023)
- Ebitda -148.95%
(FY 2023)
- Net Worth -308.82%
(FY 2023)
- Total Assets 298.17%
(FY 2023)
About Alkimia Pharma-Chem
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rajan Gadhia, Mahesh Rajnikant, and Anand Gadhia serve as directors at the Company.
- CIN/LLPIN
U24290TG2020PTC142350
- Company No.
142350
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jul 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Alkimia Pharma-Chem?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajan Gadhia  | Director | 31-Jul-2020 | Current |
| Mahesh Rajnikant | Director | 31-Jul-2020 | Current |
| Anand Gadhia | Director | 31-Jul-2020 | Current |
Financial Performance of Alkimia Pharma-Chem.
Alkimia Pharma-Chem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 27.61% increase. The company also saw a substantial fall in profitability, with a 199.63% decrease in profit. The company's net worth observed a substantial decline by a decrease of 308.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alkimia Pharma-Chem?
In 2023, Alkimia Pharma-Chem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
R.R.Innovative Private LimitedActive 12 years 9 monthsRajan Gadhia, Mahesh Rajnikant and 1 more are mutual person
- R Nandlal Sons Private LimitedActive 2 years 3 months
Rajan Gadhia, Mahesh Rajnikant and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Alkimia Pharma-Chem?
Unlock and access historical data on people associated with Alkimia Pharma-Chem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alkimia Pharma-Chem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alkimia Pharma-Chem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
